Anavex Life Sciences Corp (AVXL)

[sokol]

New and better mouse models. The mice used in the AVXL 2-73 Rett pre-clinical trial were "heterozygous MECP2 mice, a validated animal model for the disease". These mice are more predictive of success or failure. Better mouse models are now available for a number of diseases. Numerous scientific articles are are available to any one that is interested that discuss MECP2 mice for use in Rett clinical studies.

In general"

"There is a silver lining that, now, a better mouse model is available to confirm or refute promising results in traditional lab mice."
—Franck Carbonero, Washington State University

https://www.the-scientist.com/news-opinion/new-mouse-model-predicts-two-clinical-trial-failures-in-humans--66223

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome
"heterozygous MECP2 mice, a validated animal model for the disease" were used in the AVXL 2-73 study. Therefore, a comparison of the use of these specific mice to the predictive value of other mice is an apples and oranges comparison.